Novel MITF Targets Identified Using a Two-Step DNA Microarray Strategy

Total Page:16

File Type:pdf, Size:1020Kb

Novel MITF Targets Identified Using a Two-Step DNA Microarray Strategy Pigment Cell Melanoma Res. 21; 665–676 ORIGINAL ARTICLE Novel MITF targets identified using a two-step DNA microarray strategy Keith S. Hoek1, Natalie C. Schlegel1, Ossia M. Eichhoff1, Daniel S. Widmer1, Christian Praetorius2, Steingrimur O. Einarsson2,3, Sigridur Valgeirsdottir3, Kristin Bergsteinsdottir2, Alexander Schepsky2,4, Reinhard Dummer1 and Eirikur Steingrimsson2 1 Department of Dermatology, University Hospital of Zrich, Zrich, Switzerland 2 Department of Biochemistry KEYWORDS microphthalmia-associated transcrip- and Molecular Biology, Faculty of Medicine, University of Iceland, Reykjavik, Iceland 3 NimbleGen Systems of tion factor ⁄ microarray ⁄ melanoma ⁄ melanocyte ⁄ Iceland LLc, Reykjavik, Iceland 4 Signalling and Development Lab, Marie Curie Research Institute, Oxted, Surrey, transcription ⁄ correlation UK PUBLICATION DATA Received 20 June 2008, CORRESPONDENCE Keith S. Hoek, e-mail: [email protected] revised and accepted for publication 18 August 2008 doi: 10.1111/j.1755-148X.2008.00505.x Summary Malignant melanoma is a chemotherapy-resistant cancer with high mortality. Recent advances in our under- standing of the disease at the molecular level have indicated that it shares many characteristics with develop- mental precursors to melanocytes, the mature pigment-producing cells of the skin and hair follicles. The development of melanocytes absolutely depends on the action of the microphthalmia-associated transcription factor (MITF). MITF has been shown to regulate a broad variety of genes, whose functions range from pigment production to cell-cycle regulation, migration and survival. However, the existing list of targets is not sufficient to explain the role of MITF in melanocyte development and melanoma progression. DNA microarray analysis of gene expression offers a straightforward approach to identify new target genes, but standard analytical procedures are susceptible to the generation of false positives and require additional experimental steps for validation. Here, we introduce a new strategy where two DNA microarray-based approaches for identifying transcription factor targets are combined in a cross-validation protocol designed to help control false-positive generation. We use this two-step approach to successfully re-identify thirteen previously recorded targets of MITF-mediated upregulation, as well as 71 novel targets. Many of these new targets have known relevance to pigmentation and melanoma biology, and further emphasize the critical role of MITF in these processes. Introduction highly resistant to treatment and patients rarely survive longer than 10 months. The microphthalmia-associated Malignant melanoma is an aggressive form of cancer transcription factor (MITF) is a member of the basic with a high mortality rate. Although early stage disease helix-loop-helix leucine-zipper transcription factor fam- is easily treatable, advanced stages of the disease are ily and has been shown to be a critical regulator of Significance While the microphthalmia-associated transcription factor (MITF) is recognized as a master regulator for both melanocyte development and melanoma progression the number of known target genes is relatively small. This high throughput study of gene expression in melanoma cell lines serves to identify with high probability novel candidates for MITF-mediated activation in a melanocytic context. ª 2008 The Authors, Journal Compilation ª 2008 Blackwell Munksgaard 665 Hoek et al. melanocyte development and survival (Steingrimsson involved in pigmentation. Despite this variety of known et al., 2004). Various isoforms of MITF are also impor- targets MITF must regulate multiple other genes to tant for the development and homeostasis of other cell account for all aspects of MITF function during melano- types including retinal pigment epithelia, osteoclasts and cyte development and melanoma progression. Thus, in mast cells (Kawaguchi and Noda, 2000; Nechushtan order to further characterize the role of MITF in melano- et al., 1997; Planque et al., 2004). In melanoma, MITF is cyte and melanoma development, it is important to reported to be a critical factor in regulating proliferation identify additional MITF target genes. (Carreira et al., 2006; Hoek et al., 2008), and amplifica- Endogenous expression of MITF is driven by signals tion of the MITF gene is associated with poor patient which likely also activate other genes. Experiments survival (Garraway et al., 2005; Ugurel et al., 2007). where a constitutively active expression vector is used Table 1 shows that MITF is reported to regulate the to drive MITF expression short-circuit this background expression of a broad variety of genes, many of them of normally co-regulated factors. This changes the Table 1. Verification of reported Mitf target genes Symbol Title References Cell type Folda Cob ACP5 Acid phosphatase 5, tartrate resistant Luchin et al., (2000) Osteoclast 209 7 BCL2 B-cell CLL ⁄ lymphoma 2 McGill et al., (2002) Melanoma <2 7 BEST1 Bestrophin 1 Esumi et al., (2007) RPE <2 7 BIRC7 Baculoviral IAP repeat-containing 7 Dynek et al., (2008) Melanoma 214 7 CDK2 Cyclin-dependent kinase 2 Du et al., (2004) Melanocyte 3 7 CLCN7 Chloride channel 7 Meadows et al., (2007) Osteoclast 4 7 DCT Dopachrome tautomerase Yasumoto et al., (2002) Melanocyte 218 7 EDNRB Endothelin receptor type B Sato-Jin et al., (2007) Melanocyte 15 7 GPNMB Glycoprotein (transmembrane) nmb Loftus et al., (2008) Melanoblast 251 7 GPR143 G protein-coupled receptor 143 (Oa1) Vetrini et al., (2004) Melanocyte 19 6 MC1R Melanocortin 1 receptor Aoki and Moro, (2002) Melanocyte 16 4 MLANA Melan-A Du et al., (2003) Melanocyte 173 7 OSTM1 Osteopetrosis-associated transmembrane protein 1 Meadows et al., (2007) Osteoclast 5 7 RAB27A RAB27A, member RAS oncogene family Chiaverini et al., (2008) Melanocyte 13 7 SILV Silver homolog (mouse) Du et al., 2003) Melanocyte 217 7 SLC45A2 Solute carrier family 45, member 2 Du and Fisher, (2002) Melanocyte 222 7 TBX2 T-box 2 Carreira et al., (2000) Melanocyte 4 5 TRPM1 Transient receptor potential cation channel, M1 Miller et al., (2004) Melanocyte 137 6 TYR Tyrosinase Hou et al., (2000) Melanocyte 267 7 TYRP1 Tyrosinase-related protein 1 Fang et al., (2002) Melanocyte <2 7 CADM1 Cell adhesion molecule 1 Ito et al., (2003) Mast cell <2 1 CDKN1A Cyclin-dependent kinase inhibitor 1A (p21) Carreira et al., (2005) Melanocyte <2 0 CDKN2A Cyclin-dependent kinase inhibitor 2A (p16) Loercher et al., (2005) Melanocyte <2 1 Cma1 Chymase 1, mast cell Morii et al., (1997) Mast cell 7 0 CTSK Cathepsin K Motyckova et al., (2001) Osteoclast <2 1 DIAPH1 Diaphanous homolog 1 Carreira et al., (2006) Melanoma <2 1 GZMB Granzyme B Ito et al., (1998) Mast cell 10 0 HIF1A Hypoxia-inducible factor 1, alpha subunit Busca et al., (2005) Melanoma 2 0 ITGA4 Integrin, alpha 4 Kim et al., (1998) Melanocyte 3 0 KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene Tsujimura et al., 1996) Mast cell <2 2 Mcpt2 Mast cell protease 2 Ge et al., (2001) Mast cell <2 0 Mcpt4 Mast cell protease 4 Jippo et al., (1999) Mast cell <2 0 Mcpt9 Mast cell protease 9 Ge et al., (2001) Mast cell <2 0 MET Met proto-oncogene McGill et al., (2006) Melanocyte <2 3 NDST2 N-deacetylase ⁄ N-sulfotransferase 2 Morii et al., (2001) Melanocyte <2 0 NGFR Nerve growth factor receptor (p75) Jippo et al., (1997) Mast cell 3 0 OSCAR Osteoclast associated, immunoglobulin-like receptor So et al., (2003) Osteoclast 4 0 PRKCB1 Protein kinase C, beta 1 Park et al., (2006) Melanocyte 2 1 SERPINE1 Serpin peptidase inhibitor E1 (PAI-1) Murakami et al., (2006) Mast cell 6 0 SLC11A1 Solute carrier family 11, member 1 Gelineau-van Waes et al., (2008) RPE 4 1 TPH1 Tryptophan hydroxylase 1 Ito et al., (1998) Mast cell <2 0 Tpsb2 Tryptase beta 2 Morii et al., (1996) Mast cell <2 1 aFold change up on transformation of SK-MEL-28 with a Mitf-expressing vector (P < 0.05). bNumber of data sets in which correlation exceeds 0.5 with 207233_s_at (MITF). RPE, retinal pigment epithelium. 666 ª 2008 The Authors, Journal Compilation ª 2008 Blackwell Munksgaard Novel MITF targets context in which MITF operates and, in the absence of co-regulated activators and suppressors, potentially activates biologically irrelevant target genes. Alterna- tively, identification of novel MITF targets via correla- tion of mRNA expression patterns is complicated by factors which are co-regulated with MITF. This poten- tial confusion of causality and correlation also risks generating false positives. However, each of these approaches serve to complement the other. Exogenous upregulation of MITF is unlikely to activate endoge- nously co-regulated factors, and analysis of endo- genous expression patterns serves to filter out biologically irrelevant transcription activated by exoge- nous MITF expression. We show here how such a Figure 1. MAPK ⁄ JNK signalling and MITF expression. Cell two-step strategy may detect additional targets for extracts from a library of melanoma cultures were subject to MITF-driven transcription. western blotting against phosphorylated Erk1 ⁄ Erk2, phosphorylated JNK, phosphorylated p38, and b-tubulin. MITF levels, as well as BRAF and NRAS mutation status were reported previously (Hoek Results et al., 2006). These data show that neither MAPK ⁄ JNK activation nor BRAF ⁄ NRAS mutation status correlate with Mitf expression in Endogenous MAPK signalling does not affect Mitf melanoma. protein levels If a transcription factor’s function is primarily regulated by post-transcriptional or post-translational mechanisms sensitive. Nevertheless,
Recommended publications
  • BLOC-1 and BLOC-3 Regulate VAMP7 Cycling to and From
    BLOC-1 and BLOC-3 regulate VAMP7 cycling to and from melanosomes via distinct tubular transport carriers Megan K. Dennis1,2, Cédric Delevoye3,4, Amanda Acosta-Ruiz1,2, Ilse Hurbain3,4, Maryse Romao3,4, Geoffrey G. Hesketh5, Philip S. Goff6, Elena V. Sviderskaya6, Dorothy C. Bennett6, J. Paul Luzio5, Thierry Galli7, David J. Owen5, Graça Raposo3,4 and Michael S. Marks1,2,8 1Dept. of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia Research Institute, and 2Dept. of Pathology and Laboratory Medicine and Dept of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 3Institut Curie, PSL Research University, CNRS, UMR144, Structure and Membrane Compartments, F-75005, Paris, France; 4 Institut Curie, PSL Research University, CNRS, UMR144, Cell and Tissue Imaging Facility (PICT-IBiSA), F-75005, Paris, France; 5Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK; 6Cell Biology & Genetics Research Centre, St. George’s , University of London, London, UK; 7Sorbonne Paris-Cité, Univ. Paris-Diderot, Institut Jacques Monod, CNRS UMR7592, INSERM ERL U950, Membrane Traffic in Health & Disease, Paris, France. 8To whom correspondence should be addressed: Michael S. Marks, Ph.D. Dept. of Pathology & Laboratory Medicine Children's Hospital of Philadelphia Research Institute 816G Abramson Research Center 3615 Civic Center Blvd. Philadelphia, PA 19104 Tel: 215-590-3664 Email: [email protected] Running title: VAMP7 into and out of melanosomes Keywords: SNARE, lysosome-related organelle, melanogenesis, Hermansky-Pudlak syndrome, recycling, endosome, 2 ABSTRACT Endomembrane organelle maturation requires cargo delivery via fusion with membrane transport intermediates and recycling of fusion factors to their sites of origin.
    [Show full text]
  • MICAL1 Mouse Monoclonal Antibody [Clone ID: OTI6G2] Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA501844 MICAL1 Mouse Monoclonal Antibody [Clone ID: OTI6G2] Product data: Product Type: Primary Antibodies Clone Name: OTI6G2 Applications: FC, IF, WB Recommended Dilution: WB 1:500, IF 1:100, FLOW 1:100 Reactivity: Human Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Full length human recombinant protein of human MICAL1 (NP_073602) produced in HEK293T cell. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 117.7 kDa Gene Name: microtubule associated monooxygenase, calponin and LIM domain containing 1 Database Link: NP_073602 Entrez Gene 64780 Human Q8TDZ2 Background: May be a cytoskeletal regulator that connects NEDD9 to intermediate filaments Synonyms: MICAL; MICAL-1; NICAL This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 MICAL1 Mouse Monoclonal Antibody [Clone ID: OTI6G2] – TA501844 Product images: HEK293T cells were transfected with the pCMV6- ENTRY control (Left lane) or pCMV6-ENTRY MICAL1 ([RC208308], Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-MICAL1.
    [Show full text]
  • PARSANA-DISSERTATION-2020.Pdf
    DECIPHERING TRANSCRIPTIONAL PATTERNS OF GENE REGULATION: A COMPUTATIONAL APPROACH by Princy Parsana A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2020 © 2020 Princy Parsana All rights reserved Abstract With rapid advancements in sequencing technology, we now have the ability to sequence the entire human genome, and to quantify expression of tens of thousands of genes from hundreds of individuals. This provides an extraordinary opportunity to learn phenotype relevant genomic patterns that can improve our understanding of molecular and cellular processes underlying a trait. The high dimensional nature of genomic data presents a range of computational and statistical challenges. This dissertation presents a compilation of projects that were driven by the motivation to efficiently capture gene regulatory patterns in the human transcriptome, while addressing statistical and computational challenges that accompany this data. We attempt to address two major difficulties in this domain: a) artifacts and noise in transcriptomic data, andb) limited statistical power. First, we present our work on investigating the effect of artifactual variation in gene expression data and its impact on trans-eQTL discovery. Here we performed an in-depth analysis of diverse pre-recorded covariates and latent confounders to understand their contribution to heterogeneity in gene expression measurements. Next, we discovered 673 trans-eQTLs across 16 human tissues using v6 data from the Genotype Tissue Expression (GTEx) project. Finally, we characterized two trait-associated trans-eQTLs; one in Skeletal Muscle and another in Thyroid. Second, we present a principal component based residualization method to correct gene expression measurements prior to reconstruction of co-expression networks.
    [Show full text]
  • Wo 2010/075007 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075007 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) G06F 19/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/067757 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 11 December 2009 ( 11.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 12/3 16,877 16 December 2008 (16.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): DODDS, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, W., Jean [US/US]; 938 Stanford Street, Santa Monica, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, CA 90403 (US).
    [Show full text]
  • Diagnosing Platelet Secretion Disorders: Examples Cases
    Diagnosing platelet secretion disorders: examples cases Martina Daly Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Disclosures for Martina Daly In compliance with COI policy, ISTH requires the following disclosures to the session audience: Research Support/P.I. No relevant conflicts of interest to declare Employee No relevant conflicts of interest to declare Consultant No relevant conflicts of interest to declare Major Stockholder No relevant conflicts of interest to declare Speakers Bureau No relevant conflicts of interest to declare Honoraria No relevant conflicts of interest to declare Scientific Advisory No relevant conflicts of interest to declare Board Platelet granule release Agonists (FIIa, Collagen, ADP) Signals Activation Shape change Membrane fusion Release of granule contents Platelet storage organelles lysosomes a granules Enzymes including cathepsins Adhesive proteins acid hydrolases Clotting factors and their inhibitors Fibrinolytic factors and their inhibitors Proteases and antiproteases Growth and mitogenic factors Chemokines, cytokines Anti-microbial proteins Membrane glycoproteins dense (d) granules ADP/ATP Serotonin histamine inorganic polyphosphate Platelet a-granule contents Type Prominent components Membrane glycoproteins GPIb, aIIbb3, GPVI Clotting factors VWF, FV, FXI, FII, Fibrinogen, HMWK, FXIII? Clotting inhibitors TFPI, protein S, protease nexin-2 Fibrinolysis components PAI-1, TAFI, a2-antiplasmin, plasminogen, uPA Other protease inhibitors a1-antitrypsin, a2-macroglobulin
    [Show full text]
  • Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice
    Loyola University Chicago Loyola eCommons Biology: Faculty Publications and Other Works Faculty Publications 2013 Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice Mihaela Palicev Gunter P. Wagner James P. Noonan Benedikt Hallgrimsson James M. Cheverud Loyola University Chicago, [email protected] Follow this and additional works at: https://ecommons.luc.edu/biology_facpubs Part of the Biology Commons Recommended Citation Palicev, M, GP Wagner, JP Noonan, B Hallgrimsson, and JM Cheverud. "Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice." Genome Biology and Evolution 5(10), 2013. This Article is brought to you for free and open access by the Faculty Publications at Loyola eCommons. It has been accepted for inclusion in Biology: Faculty Publications and Other Works by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. © Palicev et al., 2013. GBE Genomic Correlates of Relationship QTL Involved in Fore- versus Hind Limb Divergence in Mice Mihaela Pavlicev1,2,*, Gu¨ nter P. Wagner3, James P. Noonan4, Benedikt Hallgrı´msson5,and James M. Cheverud6 1Konrad Lorenz Institute for Evolution and Cognition Research, Altenberg, Austria 2Department of Pediatrics, Cincinnati Children‘s Hospital Medical Center, Cincinnati, Ohio 3Yale Systems Biology Institute and Department of Ecology and Evolutionary Biology, Yale University 4Department of Genetics, Yale University School of Medicine 5Department of Cell Biology and Anatomy, The McCaig Institute for Bone and Joint Health and the Alberta Children’s Hospital Research Institute for Child and Maternal Health, University of Calgary, Calgary, Canada 6Department of Anatomy and Neurobiology, Washington University *Corresponding author: E-mail: [email protected].
    [Show full text]
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions
    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
    [Show full text]
  • Broad and Thematic Remodeling of the Surface Glycoproteome on Isogenic
    bioRxiv preprint doi: https://doi.org/10.1101/808139; this version posted October 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Broad and thematic remodeling of the surface glycoproteome on isogenic cells transformed with driving proliferative oncogenes Kevin K. Leung1,5, Gary M. Wilson2,5, Lisa L. Kirkemo1, Nicholas M. Riley2,4, Joshua J. Coon2,3, James A. Wells1* 1Department of Pharmaceutical Chemistry, UCSF, San Francisco, CA, USA Departments of Chemistry2 and Biomolecular Chemistry3, University of Wisconsin- Madison, Madison, WI, 53706, USA 4Present address Department of Chemistry, Stanford University, Stanford, CA, 94305, USA 5These authors contributed equally *To whom correspondence should be addressed bioRxiv preprint doi: https://doi.org/10.1101/808139; this version posted October 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract: The cell surface proteome, the surfaceome, is the interface for engaging the extracellular space in normal and cancer cells. Here We apply quantitative proteomics of N-linked glycoproteins to reveal how a collection of some 700 surface proteins is dramatically remodeled in an isogenic breast epithelial cell line stably expressing any of six of the most prominent proliferative oncogenes, including the receptor tyrosine kinases, EGFR and HER2, and downstream signaling partners such as KRAS, BRAF, MEK and AKT.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • The Role of Chromosome X in Intraocular Pressure Variation and Sex-Specific Effects
    Genetics The Role of Chromosome X in Intraocular Pressure Variation and Sex-Specific Effects Mark J. Simcoe,1–3 Anthony P. Khawaja,4,5 Omar A. Mahroo,3 Christopher J. Hammond,1,2 and Pirro G. Hysi1,2; for the UK Biobank Eye and Vision Consortium 1Department of Ophthalmology, Kings College London, London, United Kingdom 2KCL Department of Twin Research and Genetic Epidemiology, London, United Kingdom 3Institute of Ophthalmology, University College London, London, United Kingdom 4NIHR Biomedical Research Centre, Moorfield’s Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom 5Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom Correspondence: Pirro G. Hysi, PURPOSE. The purpose of this study was to identify genetic variants on chromosome Department of Ophthalmology, X associated with intraocular pressure (IOP) and determine if they possess any sex- Kings College London, St. Thomas specific effects. Hospital, Westminster Bridge Road, London, SE1 7EH UK; METHODS. Association analyses were performed across chromosome X using 102,407 [email protected]. participants from the UK Biobank. Replication and validation analyses were conducted in an additional 6599 participants from the EPIC-Norfolk cohort, and an independent Members of the UK Biobank Eye and Vision Consortium are listed in 331,682 participants from the UK Biobank. the Supplementary Material. RESULTS. We identified three loci associated with IOP at genomewide significance (P < 5 × 10−8), located within or near the following genes: MXRA5 (rs2107482, Received: June 19, 2020 − − Accepted: August 19, 2020 P = 7.1 × 10 11), GPM6B (rs66819623, P = 6.9 × 10 10), NDP,andEFHC2 (rs12558081, − Published: September 14, 2020 P = 4.9 × 10 11).
    [Show full text]
  • Nursing Genetic Research: New Insights Linking Breast Cancer Genetics and Bone Density
    healthcare Concept Paper Nursing Genetic Research: New Insights Linking Breast Cancer Genetics and Bone Density 1, 2, 3, Antonio Sanchez-Fernandez y, Raúl Roncero-Martin y, Jose M. Moran * , Jesus Lavado-García 2 , Luis Manuel Puerto-Parejo 2 , Fidel Lopez-Espuela 2, Ignacio Aliaga 3 and María Pedrera-Canal 2 1 Servicio de Tocoginecología, Complejo Hospitalario de Cáceres, 10004 Cáceres, Spain; [email protected] 2 Metabolic Bone Diseases Research Group, Nursing Department, Nursing and Occupational Therapy College, University of Extremadura, Avd. Universidad s/n, 10003 Cáceres, Spain; [email protected] (R.R.-M.); [email protected] (J.L.-G.); [email protected] (L.M.P.-P.); fi[email protected] (F.L.-E.); [email protected] (M.P.-C.) 3 Departamento de Estomatología II, Universidad Complutense de Madrid, 28040 Madrid, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-927-257450 Both authors contributed equally to this work. y Received: 25 April 2020; Accepted: 11 June 2020; Published: 15 June 2020 Abstract: Nursing research is expected to provide options for the primary prevention of disease and health promotion, regardless of pathology or disease. Nurses have the skills to develop and lead research that addresses the relationship between genetic factors and health. Increasing genetic knowledge and research capacity through interdisciplinary cooperation as well as the development of research resources, will accelerate the rate at which nurses contribute to the knowledge about genetics and health. There are currently different fields in which knowledge can be expanded by research developed from the nursing field. Here, we present an emerging field of research in which it is hypothesized that genetics may affect bone metabolism.
    [Show full text]
  • Taf7l Cooperates with Trf2 to Regulate Spermiogenesis
    Taf7l cooperates with Trf2 to regulate spermiogenesis Haiying Zhoua,b, Ivan Grubisicb,c, Ke Zhengd,e, Ying Heb, P. Jeremy Wangd, Tommy Kaplanf, and Robert Tjiana,b,1 aHoward Hughes Medical Institute and bDepartment of Molecular and Cell Biology, Li Ka Shing Center for Biomedical and Health Sciences, California Institute for Regenerative Medicine Center of Excellence, University of California, Berkeley, CA 94720; cUniversity of California Berkeley–University of California San Francisco Graduate Program in Bioengineering, University of California, Berkeley, CA 94720; dDepartment of Animal Biology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104; eState Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 210029, People’s Republic of China; and fSchool of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem 91904, Israel Contributed by Robert Tjian, September 11, 2013 (sent for review August 20, 2013) TATA-binding protein (TBP)-associated factor 7l (Taf7l; a paralogue (Taf4b; a homolog of Taf4) (9), TBP-related factor 2 (Trf2) (10, of Taf7) and TBP-related factor 2 (Trf2) are components of the core 11), and Taf7l (12, 13). For example, mice bearing mutant or promoter complex required for gene/tissue-specific transcription deficient CREM showed decreased postmeiotic gene expression of protein-coding genes by RNA polymerase II. Previous studies and defective spermiogenesis (14). Mice deficient in Taf4b, reported that Taf7l knockout (KO) mice exhibit structurally abnor- a testis-specific homolog of Taf4, are initially normal but undergo mal sperm, reduced sperm count, weakened motility, and compro- progressive germ-cell loss and become infertile by 3 mo of age −/Y mised fertility.
    [Show full text]